Source: Pharmacological Reports. Unidade: FMRP
Assunto: ANTI-INFLAMATÓRIOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Aline C. Brando et al. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, v. 63, n. 4, p. 1029-1039, 2011Tradução . . Disponível em: https://doi.org/10.1016/s1734-1140(11)70619-3. Acesso em: 14 out. 2024.APA
Lima, A. C. B., Machado, A. L., Simon, P., Cavalcante, M. M., Rezende, D. C., Silva, G. M. S., et al. (2011). Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, 63( 4), 1029-1039. doi:10.1016/s1734-1140(11)70619-3NLM
Lima ACB, Machado AL, Simon P, Cavalcante MM, Rezende DC, Silva GMS, Nascimento PGBD, Quintas LEM, Cunha F de Q, Barreiro EJ, Lima LM, Koatz VLG. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation [Internet]. Pharmacological Reports. 2011 ; 63( 4): 1029-1039.[citado 2024 out. 14 ] Available from: https://doi.org/10.1016/s1734-1140(11)70619-3Vancouver
Lima ACB, Machado AL, Simon P, Cavalcante MM, Rezende DC, Silva GMS, Nascimento PGBD, Quintas LEM, Cunha F de Q, Barreiro EJ, Lima LM, Koatz VLG. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation [Internet]. Pharmacological Reports. 2011 ; 63( 4): 1029-1039.[citado 2024 out. 14 ] Available from: https://doi.org/10.1016/s1734-1140(11)70619-3